ATE304533T1 - Tetrahydrochinolinderivate als muscarinische agonisten - Google Patents

Tetrahydrochinolinderivate als muscarinische agonisten

Info

Publication number
ATE304533T1
ATE304533T1 AT02794441T AT02794441T ATE304533T1 AT E304533 T1 ATE304533 T1 AT E304533T1 AT 02794441 T AT02794441 T AT 02794441T AT 02794441 T AT02794441 T AT 02794441T AT E304533 T1 ATE304533 T1 AT E304533T1
Authority
AT
Austria
Prior art keywords
compounds
muscarinic agonists
methods
muscarinic receptor
tetrahydrochinoline
Prior art date
Application number
AT02794441T
Other languages
English (en)
Inventor
Niels Skjaerbaek
Kristian Norup Koch
Bo Lennart Mikael Friberg
Bo-Ragnar Tolf
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of ATE304533T1 publication Critical patent/ATE304533T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02794441T 2001-12-28 2002-12-23 Tetrahydrochinolinderivate als muscarinische agonisten ATE304533T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34472201P 2001-12-28 2001-12-28
PCT/US2002/041617 WO2003057672A2 (en) 2001-12-28 2002-12-23 Tetrahydroquinoline analogues as muscarinic agonists

Publications (1)

Publication Number Publication Date
ATE304533T1 true ATE304533T1 (de) 2005-09-15

Family

ID=23351729

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794441T ATE304533T1 (de) 2001-12-28 2002-12-23 Tetrahydrochinolinderivate als muscarinische agonisten

Country Status (19)

Country Link
US (3) US7307075B2 (de)
EP (1) EP1461318B9 (de)
JP (1) JP4509565B2 (de)
KR (1) KR100972614B1 (de)
CN (1) CN100402032C (de)
AT (1) ATE304533T1 (de)
AU (1) AU2002359875B2 (de)
BR (1) BR0215430A (de)
CA (1) CA2470578C (de)
DE (1) DE60206198T2 (de)
DK (1) DK1461318T3 (de)
ES (1) ES2251624T3 (de)
IL (2) IL162616A0 (de)
MX (1) MXPA04006281A (de)
NO (1) NO327522B1 (de)
NZ (1) NZ533566A (de)
RU (1) RU2292346C2 (de)
WO (1) WO2003057672A2 (de)
ZA (1) ZA200405024B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
WO2003057672A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP1613321A2 (de) * 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinische m1 rezeptor-agonisten für die schmerzbehandlung
WO2006137485A1 (ja) * 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0607949D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
CA2659412A1 (en) * 2006-07-31 2008-02-07 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2326644B1 (de) 2008-08-02 2012-02-22 Janssen Pharmaceutica N.V. Urotensin-ii-rezeptorantagonisten
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013072705A1 (en) 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
EP4447953A1 (de) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Kombination aus muskarinrezeptor-positiven modulatoren und nmda-positiven allosterischen modulatoren

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324137A (en) * 1964-05-08 1967-06-06 Sterling Drug Inc N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes
US3365457A (en) * 1964-05-08 1968-01-23 Sterling Drug Inc N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives
JPS63290821A (ja) * 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
JP2886570B2 (ja) * 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
US5149815A (en) * 1991-04-29 1992-09-22 American Home Products Corporation N-substituted-2-aminoquinolines
US5378698A (en) 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5457099A (en) * 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
DE4228095A1 (de) 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
TW448161B (en) * 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
JP4108123B2 (ja) * 1995-09-29 2008-06-25 グラクソスミスクライン・ソシエタ・ペル・アチオニ Nmdaアンタゴニストとしてのテトラヒドロキノリン
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
EP0934932A4 (de) 1996-08-22 2002-06-26 Meiji Seika Kaisha Chinolinderivate und psychotropes mittel
US5919750A (en) * 1997-07-24 1999-07-06 Akzo Nobel Nv Fabric softener composition
KR100672186B1 (ko) * 1998-03-31 2007-01-19 아카디아 파마슈티칼스 인코포레이티드 무스카린 수용체에 대해 활성을 갖는 화합물
WO1999050257A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Benzoxazinones/benzothiazinones as serine protease inhibitors
WO2001027104A1 (en) * 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
TR200402408T4 (tr) * 1999-12-30 2004-12-21 H. Lundbeck A/S 4-fenil-1-piperazinil,-piperidinil ve-tetrahidropiridil türevleri
PT1260512E (pt) * 2000-02-29 2007-10-10 Mitsubishi Pharma Corp ''novos derivados de amida cíclicos''
CA2407594A1 (en) * 2000-04-28 2001-11-08 Acadia Pharmaceuticals, Inc. Muscarinic agonists
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003057672A2 (en) 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
EP1613321A2 (de) 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinische m1 rezeptor-agonisten für die schmerzbehandlung

Also Published As

Publication number Publication date
EP1461318A2 (de) 2004-09-29
ZA200405024B (en) 2005-07-27
NO20043013L (no) 2004-07-28
NO327522B1 (no) 2009-08-03
IL162616A0 (en) 2005-11-20
US20060199810A1 (en) 2006-09-07
IL162616A (en) 2011-06-30
ES2251624T3 (es) 2006-05-01
KR20040070287A (ko) 2004-08-06
DE60206198D1 (de) 2005-10-20
JP2005519060A (ja) 2005-06-30
MXPA04006281A (es) 2004-09-27
AU2002359875B2 (en) 2009-01-08
RU2004123203A (ru) 2006-01-20
CA2470578A1 (en) 2003-07-17
WO2003057672A2 (en) 2003-07-17
CN1635891A (zh) 2005-07-06
BR0215430A (pt) 2004-12-14
AU2002359875A1 (en) 2003-07-24
JP4509565B2 (ja) 2010-07-21
US7307075B2 (en) 2007-12-11
CA2470578C (en) 2010-10-12
EP1461318B1 (de) 2005-09-14
US20060199813A1 (en) 2006-09-07
RU2292346C2 (ru) 2007-01-27
US20030176418A1 (en) 2003-09-18
NZ533566A (en) 2007-03-30
US7576100B2 (en) 2009-08-18
HK1074573A1 (zh) 2005-11-18
KR100972614B1 (ko) 2010-07-27
CN100402032C (zh) 2008-07-16
WO2003057672A3 (en) 2003-11-13
DK1461318T3 (da) 2006-01-09
US7576078B2 (en) 2009-08-18
EP1461318B9 (de) 2005-12-28
DE60206198T2 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
DE60236206D1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
MA27933A1 (fr) Inhibiteurs de l&#39;activite de akt
NO20013443D0 (no) Triazolforbindelser med dopamin-D3-reseptoraktivitet
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
EA200200208A1 (ru) Синергитическая композиция
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu&#39;antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
WO2003105840A3 (en) Sphingosine kinase inhibitors
ATE328879T1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
ATE355288T1 (de) Verbindungen und therapeutische methoden
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
DE60239711D1 (de) Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten zur Behandlung von bipolarer Störung
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1461318

Country of ref document: EP